fbpx

U.S. Anti-Doping Agency (USADA)

Global DRO logo in whiteSearch Medications & Ingredients

Independent Panel Grants Motion to Postpone in Danielson Case

Tom Danielson Cycling DopingThe American Arbitration Association (AAA) panel overseeing the case of cyclist Tom Danielson has granted a motion made by Mr. Danielson’s counsel to postpone his arbitration hearing. Mr. Danielson will remain provisionally suspended, and the hearing originally scheduled for June, will move to a yet-to-be-determined date in the fall.

Mr. Danielson previously announced his positive test, which USADA confirmed was for an anabolic agent found through Carbon Isotope Ratio (CIR) testing. While USADA was prepared to move forward with the scheduled June hearing, Mr.  Danielson’s counsel requested a postponement in order to conduct further analysis of supplements he was using at the time of sample collection.

The independent panel will immediately begin the process of setting a new date for the hearing.

In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, the agency manages a drug reference hotline, Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, periodic newsletters, and protocol and policy reference documentation.

USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement, and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.


For more information or media inquiries, click here.

Scroll to Top